The RCT BioVentures program is the vehicle through which Research Corporation Technologies invests in start-up or early-stage companies whose technologies promise patented biomedical products with a clear competitive advantage.
RCT has assets of more than $300 million to advance technology development through flexible, long-term investment options. Our initial financial commitment to our portfolio companies usually ranges from several hundred thousand dollars to several million dollars, and we reserve additional funds for the subsequent funding of successful companies. We can also invest management resources if needed.
Within the United Kingdom and Australia, RCT BioVentures invests through Cambridge Research BioVentures Ltd. (CRB) and BioVentures Australia Pty. RCT launched CRB with Cambridge-based Emerging Technology Services Limited (ETS) in 2000 to support early development of promising biomedical and life sciences discoveries in the United Kingdom and Ireland. Start-up Australia and RCT formed BioVentures Australia in March 1999 to invest in life science and medical technologies originating in Australia.
Current Areas of Interest
Our current interests include new life-sciences platforms, and preclinical and clinical-stage therapeutics, devices (see: Medical Devices PDF) and diagnostics in the areas of:
- Autoimmune disorders
- Cancer and supportive care (see: Oncology PDF)
- Cardiovascular diseases (see: Cardiovascular PDF)
- Dermatologic disorders
- Diabetes & metabolic diseases
- Gastrointestinal disorders
- Inflammation (see: Inflammation PDF)
- Neurologic disorders
- Obesity
- Ophthalmological diseases (see: Ophthalmology PDF)
- Pain
- Pulmonary disorders
Our current portfolio companies in the United States, Canada, Australia and the United Kingdom are developing a variety of innovative drugs, diagnostics and devices to help meet these worldwide healthcare needs.
Tell Us About Your Company
If your company meets our criteria and needs further development and commercialization, we would like to hear from you. Please contact us to begin a confidential review of your opportunity.
